Hayley Virgil

Data from the phase 3 JAVELIN Ovarian 200 trial indicated that avelumab with or without pegylated liposomal doxorubicin did not yield a significant improvement in overall or progression-free survival over the chemotherapy alone in platinum-resistant/refractory ovarian cancer.

New research indicate that men with positive pelvic lymph nodes or a prostatectomy Gleason score of 8 to 10 with disease extending beyond the prostate may benefit most from adjuvant radiation therapy

Phase 1 data presented at 2021 EHA indicate that a high rate of response was associated with zandelisib plus zanubrutinib therapy in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia.

Adding toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses for patients with advanced hepatocellular carcinoma.

Larotrectinib’s tumor-agnostic indication for NTRK fusion–positive cancers is further validated by data presented at the 2021 ASCO Annual Meeting.

Results reported at the 2021 ASCO Annual Meeting show that half of patients treated in the FORWARD II trial achieved a response to therapy with mirvetuximab soravtansine and bevacizumab.

Phase 2 results presented during the 2021 ASCO Annual Meeting suggest durvalumab plus chemotherapy as neoadjuvant therapy for triple-negative breast cancer may be beneficial in certain patients.

Successful treatment of patients with Philadelphia chromosome–positive acute lymphocytic leukemia was noted with ponatinib plus blinatumomab, denoted by complete and major molecular responses.

Progression-free survival more than doubled when relatlimab was added to nivolumab to treated patients with previously untreated, unresectable or metastatic melanoma.

The majority of independently adjudicated interstitial lung disease cases associated with the antibody-drug conjugate were low grade and occurred within the first 12 months of treatment.

The combination adjuvant treatment of ipilimumab plus nivolumab did not meet the dual primary endpoints of the phase 3 CheckMate-915 trial, failing to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations.

Patients with EGFR-positive non–small cell lung cancer who received treatment with osimertinib following surgery versus placebo experienced no clinically meaningful differences in health-related quality of life, according to results of a pivotal phase 3 trial.

In non-muscle invasive bladder cancer carcinoma in-situ that is not responsive to BCG alone, the addition of N-803 leads to efficacy while maintaining safety.

Savolitinib plus osimertinib overcomes treatment resistance in non–small cell lung cancer with oncogenic driver mutations.

Overall self-reported quality of life in patients with metastatic pancreatic cancer was correlated with their mean daily step count during the first 2 weeks of treatment on SM-88.

Rates of survival increased in step with treatment duration of liposomal irinotecan plus 5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma.

Neoadjuvant atezolizumab added to nab-paclitaxel followed by doxorubicin plus cyclophosphamide improved pathologic complete responses compared with placebo plus chemotherapy in patients with early triple-negative breast cancer without adding additional treatment burden.

PreciseDx, an artificial intelligence–digital breast cancer risk discrimination platform, was able to classify patients with Oncotype Dx low-risk recurrence scores with high accuracy using only hematoxylin and eosin stain images and limited clinical data.

Data from initial dose cohorts of a phase 1/2 trial indicated the agent was found to safely drive natural killer cell proliferation in patients with high-risk myelodysplastic syndromes and acute myeloid leukemia.

The BCMA- and CD3-targeted bispecific monoclonal antibody, demonstrated early, deep, and durable responses with acceptable safety and tolerability in patients with relapsed/refractory multiple myeloma.

Post-operative radiotherapy was associated with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non-small cell lung cancer and therefore cannot be recommended as a standard of care.

The addition of nivolumab (Opdivo) to chemotherapy resulted in a statistically significant improvement in PFS and evoked higher ORRs in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer.